Pregabalin Solution
Product Images NDC 39328-090

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 39328-090). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Patrin Pharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Pregabalin 01)

Chemical structure of pregabalin, the active ingredient in PREGABALIN oral solution 20 mg/mL by Patrin Pharma, Inc. The structure shows the molecular arrangement including amino and carboxylic acid functional groups.*

FDA Label Image

Figure 1 (Pregabalin 02)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for oral Pregabalin solution at doses of 25 mg, 100 mg, and 200 mg taken three times a day, compared to placebo. Higher doses of Pregabalin show a greater percentage of patients with pain improvement relative to placebo.*

FDA Label Image

Figure 2 (Pregabalin 03)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline. It shows two lines representing patients treated with Pregabalin 100 mg three times a day and placebo. The y-axis is labeled 'Percent of Patients Improved' and the x-axis is labeled 'Percent Improvement in Pain from Baseline.' Vertical lines mark increments along the x-axis. The Pregabalin line consistently shows higher patient improvement percentages than the placebo line.*

FDA Label Image

Figure 3 (Pregabalin 04)

A line graph comparing percent improvement in pain from baseline against percent of patients improved for Pregabalin oral solution at doses 75 mg, 150 mg, and 300 mg taken two times a day, and placebo. The graph shows dose-dependent trends in patient pain improvement percentage with higher doses showing greater improvement curves than placebo.*

FDA Label Image

Figure 4 (Pregabalin 05)

A line graph comparing the percent of patients improved based on the percent improvement in pain from baseline among three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The vertical axis shows the percent of patients improved, and the horizontal axis shows the percent improvement in pain from baseline.*

FDA Label Image

Figure 5 (Pregabalin 06)

A line graph showing the percent of patients who improved plotted against percent improvement in pain from baseline for PREGABALIN 100 mg three times a day, PREGABALIN 50 mg three times a day, and placebo. The graph compares the effectiveness of these treatments in reducing pain.*

FDA Label Image

Figure 6 (Pregabalin 07)

Bar graph depicting responder rates (%) from Studies E1 and E3, comparing placebo and various dosages of pregabalin taken daily. The x-axis shows treatment groups including placebo and pregabalin doses (50 mg/day to 600 mg/day). The y-axis measures responder rates from 0% to 60%. The graph indicates increased responder rates with higher pregabalin doses compared to placebo.*

FDA Label Image

Figure 7 (Pregabalin 08)

A line graph depicting seizure reduction as median percent change from baseline versus dose (mg/day) for four studies labeled E1 BD, E2 TD, E3 BD, and E3 TD. Each study's data points are marked with different symbols, showing increasing seizure reduction with higher doses. Significant p-values are noted near data points, indicating statistical significance of the results.*

FDA Label Image

Figure 8 (Pregabalin 09)

A bar graph showing responder rates in percentages for three treatment groups: Placebo (22.6%, N=93), 2.5 mg/kg/day (29.1%, N=103), and 10 mg/kg/day (40.6%, N=96). The vertical axis represents responder rate percentage, and the horizontal axis lists the treatment groups with respective sample sizes.*

FDA Label Image

Figure 9 (Pregabalin 10)

A line chart depicting the percent of patients improved plotted against percent improvement in pain from baseline. The chart includes curves for Pregabalin at daily doses of 600 mg, 450 mg, and 300 mg, compared to a placebo. The y-axis shows the percent of patients improved, while the x-axis represents percent improvement in pain, ranging from 0 to over 100 percent.*

FDA Label Image

Figure 10 (Pregabalin 11)

A line graph comparing the estimated percentage of subjects without LTR over 180 days for Pregabalin versus Placebo. The graph shows two lines: a solid line for Pregabalin and a dashed line for Placebo, with the Y-axis representing percentage from 0% to 100% and the X-axis representing time in days from 0 to 180.*

FDA Label Image

Figure 11 (Pregabalin 12)

A line chart comparing the percent of subjects improved from baseline to Week 12 using the BOCF method for Pregabalin 20 mg/mL oral solution versus placebo. The x-axis shows percent improvement from 0 to 100%, and the y-axis shows the percent of subjects improved, with Pregabalin showing higher improvement rates than placebo across the range.*

FDA Label Image

Figure 12 (Pregabalin 13)

A line graph comparing the percent of subjects improved over various percent improvement intervals from baseline to week 16 using the BOCF method. The solid line represents Pregabalin, showing higher improvement percentages compared to the placebo represented by a dashed line. The x-axis indicates percent improvement from greater than 0 to 100, and the y-axis shows the percent of subjects improved from 0 to 100.*

FDA Label Image

Principal Display Panel (473 mL Bottle Label)

Label for Pregabalin Oral Solution 20 mg/mL by Patrin Pharma, Inc. The label indicates the solution is for oral use only and includes storage instructions, dispensing requirements, and dosage guidance. The container size is 16 fl oz (473 mL), with the product made in the USA.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.